Jun 02 2025
 Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

Posted at Jun 02 2025
h in News by

DUBLIN, May 29, 2025 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. ALKS 2680 is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).

Check out the full article here.

Print page